Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1993 2
1994 4
1995 2
1996 4
1997 1
1998 2
1999 3
2002 2
2003 2
2005 4
2006 2
2007 1
2008 1
2009 3
2010 4
2011 3
2012 2
2013 2
2014 3
2015 6
2019 2
2021 1
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Results by year

Filters applied: . Clear all
Page 1
Feasibility and patient acceptability of a commercially available wearable and a smart phone application in identification of motor states in parkinson's disease.
Liikkanen S, Sinkkonen J, Suorsa J, Kaasinen V, Pekkonen E, Kärppä M, Scheperjans F, Huttunen T, Sarapohja T, Pesonen U, Kuoppamäki M, Keränen T. Liikkanen S, et al. Among authors: kuoppamaki m. PLOS Digit Health. 2023 Apr 7;2(4):e0000225. doi: 10.1371/journal.pdig.0000225. eCollection 2023 Apr. PLOS Digit Health. 2023. PMID: 37027348 Free PMC article.
Entacapone and prostate cancer risk in patients with Parkinson's disease.
Korhonen P, Kuoppamäki M, Prami T, Hoti F, Christopher S, Ellmén J, Aho V, Vahteristo M, Pukkala E, Haukka J. Korhonen P, et al. Among authors: kuoppamaki m. Mov Disord. 2015 Apr 15;30(5):724-8. doi: 10.1002/mds.26140. Epub 2015 Jan 16. Mov Disord. 2015. PMID: 25639262
Oral levosimendan in amyotrophic lateral sclerosis: a phase II multicentre, randomised, double-blind, placebo-controlled trial.
Al-Chalabi A, Shaw P, Leigh PN, van den Berg L, Hardiman O, Ludolph A, Aho VV, Sarapohja T, Kuoppamäki M. Al-Chalabi A, et al. Among authors: kuoppamaki m. J Neurol Neurosurg Psychiatry. 2019 Oct;90(10):1165-1170. doi: 10.1136/jnnp-2018-320288. Epub 2019 Jul 17. J Neurol Neurosurg Psychiatry. 2019. PMID: 31315908 Free PMC article. Clinical Trial.
Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial.
Cudkowicz M, Genge A, Maragakis N, Petri S, van den Berg L, Aho VV, Sarapohja T, Kuoppamäki M, Garratt C, Al-Chalabi A; REFALS investigators. Cudkowicz M, et al. Among authors: kuoppamaki m. Lancet Neurol. 2021 Oct;20(10):821-831. doi: 10.1016/S1474-4422(21)00242-8. Lancet Neurol. 2021. PMID: 34536404
Does levodopa accelerate the pathologic process in Parkinson disease brain?
Parkkinen L, O'Sullivan SS, Kuoppamäki M, Collins C, Kallis C, Holton JL, Williams DR, Revesz T, Lees AJ. Parkkinen L, et al. Among authors: kuoppamaki m. Neurology. 2011 Oct 11;77(15):1420-6. doi: 10.1212/WNL.0b013e318232ab4c. Epub 2011 Sep 14. Neurology. 2011. PMID: 21917769
55 results